Correction to: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (Gene Therapy, (2016), 23, 12, (857-862), 10.1038/gt.2016.66);Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

Gene Therapy

Volumn 23, Issue 12, 2016, Pages 857-862

  Georgiadis, A ^a   Duran, Y ^a   Ribeiro, J ^a   Abelleira Hervas, L ^a   Robbie, S J ^a   Sunkel Laing B ^a   Fourali, S ^a   Gonzalez Cordero, A ^a   Cristante, E ^a   Michaelides, M ^a   Bainbridge, J W B ^a,b   Smith, A J ^a,b   Ali, R R ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

65 KDA RETINAL PIGMENT EPITHELIUM SPECIFIC RETINOID ISOMERASE; ADENOVIRUS VECTOR; ISOMERASE; MESSENGER RNA; UNCLASSIFIED DRUG; CIS TRANS ISOMERASE; RETINOID ISOMEROHYDROLASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CODON; CONTROLLED STUDY; ELECTRORETINOGRAPHY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INDUCED PLURIPOTENT STEM CELL; LEBER CONGENITAL AMAUROSIS; MALE; MOUSE; NONHUMAN; OBSTETRIC DELIVERY; PHOTORECEPTOR; PHOTORECEPTOR CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RETINA DEGENERATION; RETINAL THICKNESS; RETINOTOMY; RNA STABILITY; SEROTYPE; SUBRETINAL DRUG ADMINISTRATION; TRANSCRIPTION INITIATION SITE; VIRAL GENE THERAPY; YOUNG ADULT; 3T3 CELL LINE; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HEK293 CELL LINE; METABOLISM; PROCEDURES; RABBITS AND HARES;

3T3 CELLS; ANIMALS; CIS-TRANS-ISOMERASES; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; LEBER CONGENITAL AMAUROSIS; MALE; MICE; MICE, INBRED C57BL; RABBITS;

EID: 84988661136     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/s41434-018-0031-x     Document Type: Erratum

References (20)

1. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008; 27: 391-419.
2. Takahashi Y, Moiseyev G, Chen Y, Nikolaeva O, Ma JX. An alternative isomerohydrolase in the retinal Muller cells of a cone-dominant species. FEBS J 2011; 278: 2913-2926.
3. Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet 1998; 20: 344-351.
4. Pang JJ, Chang B, Kumar A, Nusinowitz S, Noorwez SM, Li J et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 2006; 13: 565-572.
5. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12: 1072-1082.
6. Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015; 372: 1887-1897.
7. Mowat FM, Breuwer AR, Bartoe JT, Annear MJ, Zhang Z, Smith AJ et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Therapy 2013; 20: 545-555.
8. Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
9. Maguire AM, Simonelli F, Pierce EA, Pugh Jr. EN, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
10. Hauswirth W, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Phase I trial of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results. Hum Gene Therapy 2008; 19: 979-990.
11. Banin E, Gootwine E, Obolensky A, Ezra-Elia R, Ejzenberg A, Zelinger L et al. Gene augmentation therapy restores retinal function and visual behavior in a sheep model of CNGA3 achromatopsia. Mol Ther 2015; 23: 1423-1433.
12. Weleber RG, Pennesi ME, Wilson DJ, Kaushal S, Erker LR, Jensen L et al. Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology 2016; 123: 1606-1620.
13. Annear MJ, Bartoe JT, Barker SE, Smith AJ, Curran PG, Bainbridge JW et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Therapy 2011; 18: 53-61.
14. Jacobson SG, Cideciyan AV, Roman AJ, Sumaroka A, Schwartz SB, Heon E et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 2015; 372: 1920-1926.
15. Bali V, Bebok Z. Decoding mechanisms by which silent codon changes influence protein biogenesis and function. Int J Biochem Cell Biol 2015; 64: 58-74.
16. Jacobs JB, Dell'Osso LF, Wang ZI, Acland GM, Bennett J. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci 2009; 50: 4685-4692.
17. Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012; 130: 9-24.
18. Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, McMillan EL et al. Modeling early retinal development with human embryonic and induced pluripotent stem cells. Proc Natl Acad Sci USA 2009; 106: 16698-16703.
19. Meyer JS, Howden SE, Wallace KA, Verhoeven AD, Wright LS, Capowski EE et al. Optic vesicle-like structures derived from human pluripotent stem cells facilitate a customized approach to retinal disease treatment. Stem Cells 2011; 29: 1206-1218.
20. Nishiguchi KM, Carvalho LS, Rizzi M, Powell K, Holthaus SM, Azam SA et al. Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179. Nat Commun 2015; 6: 6006.